Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

PGXL and Silicon Biosystems Collaborate

Published: Friday, April 26, 2013
Last Updated: Friday, April 26, 2013
Bookmark and Share
Companies to offer clinical research services focused on oncology genomics.

PGXL Technologies and Silicon Biosystems, Inc. announced a collaborative partnership to make the highly regarded Silicon Biosystems DEPArray technology available through PGXL Technologies. The PGXL program will allow clinical researchers and pharma sponsors to obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research.

“As the DEPArray technology has gained recognition in the marketplace for its unmatched ability to recover pure cells for molecular characterization, we have received significant interest in having the platform available on a fee-for-service basis,” said Bob Proulx, President and General Manager of Silicon Biosystems’ U.S. operations. “Last year we added a demonstration and training lab, but partnering with PGXL for CRO services will add a whole new dimension to our ability to reach and impact the market.”

The DEPArray technology has broad application in the study of the underlying causes of disease, disease progression and the basis of drug resistance and efficacy. Recent technology progress in the areas of DNA and RNA analysis have shown that the complexity of diseases, like cancer, will require the characterization and comparison of different types of samples at the single cell level. The DEPArray system provides single-cell sorting, and can deliver the cell purity needed for the stringent downstream applications, such as next-gen sequencing and RNA expression profiling.

“We partnered with PGXL because they bring highly complementary capabilities and expertise to the equation,” Proulx continued. “Their experience in molecular methods and operation of a CLIA laboratory make them an ideal service provider for our prospective clients interested in genomic heterogeneity and translational research.”

“PGXL Tech exists to bring to market technologies that advance personalized medicine,” said Dr. Roland Valdes, Jr., President of PGXL Laboratories. “Making the DEPArray available on a fee-for-service basis empowers researchers to work with a precision that will speed discovery.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos